BR9811594A - Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion - Google Patents

Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion

Info

Publication number
BR9811594A
BR9811594A BR9811594-4A BR9811594A BR9811594A BR 9811594 A BR9811594 A BR 9811594A BR 9811594 A BR9811594 A BR 9811594A BR 9811594 A BR9811594 A BR 9811594A
Authority
BR
Brazil
Prior art keywords
compounds
leukocyte adhesion
vla
sulphonylated
mediated leukocyte
Prior art date
Application number
BR9811594-4A
Other languages
Portuguese (pt)
Inventor
Eugene D Thorsett
Christopher M Semko
Michael A Pleiss
Anthony Kreft
Francine S Grant
Reinhardt Bernhard Baudy
Dimitrios Sarantakis
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of BR9811594A publication Critical patent/BR9811594A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção:<B>"COMPOSTOS DE DIPEPTìDEO SULFONILADOS QUE INIBEM ADESãO DE LEUCóCITOS MEDIADA POR VLA-4"<D>. Descritos são os compostos que ligam VLA-4. Certos desses compostos também inibem adesão de leucócito e, em particular, adesão de leucócito mediada por VLA-4. Tais compostos são úteis no tratamento de doenças inflamatórias em um paciente mamífero, por exemplo, ser humano, tais como asma, doença de Alzheimer, aterosclerose, demência da AIDS, diabetes, doença de intestino inflamatório, artrite reumatóide, transplante de tecido, metástase de tumor e isquemia miocardial. Os compostos podem também ser administrados para o tratamento de doenças de cérebro inflamatórias tal como esclerose múltipla.Invention Patent: <B> "SULPHONYLATED DIPEPTIDE COMPOUNDS INHIBIT VLA-4 MEDIATED LEUKOCYTE ADHESION" <D>. Described are the compounds that bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, VLA-4 mediated leukocyte adhesion. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, for example, a human being, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, metastasis of tumor and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

BR9811594-4A 1997-07-31 1998-07-31 Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion BR9811594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90442397A 1997-07-31 1997-07-31
PCT/US1998/016070 WO1999006437A1 (en) 1997-07-31 1998-07-31 Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
BR9811594A true BR9811594A (en) 2000-09-05

Family

ID=25419137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811594-4A BR9811594A (en) 1997-07-31 1998-07-31 Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion

Country Status (12)

Country Link
EP (1) EP0994896A1 (en)
JP (1) JP2001512139A (en)
KR (1) KR20010022405A (en)
CN (1) CN1265672A (en)
AU (1) AU8823498A (en)
BR (1) BR9811594A (en)
CA (1) CA2290748A1 (en)
HU (1) HUP0003921A3 (en)
IL (1) IL133637A0 (en)
NO (1) NO20000452L (en)
PL (1) PL338457A1 (en)
WO (1) WO1999006437A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
DK0991619T3 (en) 1997-06-23 2003-12-29 Tanabe Seiyaku Co Inhibitors of alpha 4-beta 1-mediated cell adhesion
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ATE267168T1 (en) * 1997-11-24 2004-06-15 Merck & Co Inc BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1056714B1 (en) 1998-02-26 2004-08-11 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2000048994A1 (en) * 1999-02-18 2000-08-24 F. Hoffmann-La Roche Ag Thioamide derivatives
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
EP1741428A3 (en) * 1999-08-13 2007-05-09 Biogen Idec MA, Inc. Cell adhesion inhibitors
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP2003519697A (en) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク Non-peptide VLA-4-dependent cell binding inhibitors useful for the treatment of inflammatory diseases, autoimmune diseases and respiratory diseases
WO2001068586A2 (en) * 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
ATE375330T1 (en) 2000-04-17 2007-10-15 Ucb Pharma Sa ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
JP2004502762A (en) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド Squaric acid derivatives as integrin antagonists containing bicyclic heteroaromatic rings
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
ATE497385T1 (en) 2000-08-18 2011-02-15 Ajinomoto Kk NEW PHENYLALANINE DERIVATIVES
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
US6607735B2 (en) 2000-12-21 2003-08-19 Johnson & Johnson Consumer Companies, Inc. Method for reducing the appearance of dark circles under the eyes
JP2004526733A (en) 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
US6559174B2 (en) 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6855708B2 (en) 2001-03-20 2005-02-15 Merck & Co., Inc. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
EP1477482B1 (en) * 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
EP1592386A4 (en) * 2003-01-24 2007-06-13 Elan Pharm Inc Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
UY28391A1 (en) * 2003-06-25 2004-12-31 Elan Pharm Inc METHODS AND COMPOSITIONS TO TREAT REUMATOID ARTHRITIS
EP1683525B1 (en) * 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
ES2360064T3 (en) * 2003-11-14 2011-05-31 Ajinomoto Co., Inc. SOLID DISPERSION OR MEDICINAL SOLID DISPERSION PREPARATION OF A PHENYLALANINE DERIVATIVE.
EP1968635B1 (en) * 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP6007417B2 (en) 2011-05-31 2016-10-12 レセプトス エルエルシー Novel GLP-1 receptor stabilizer and modulator
AU2012352349B2 (en) * 2011-12-12 2017-08-17 Receptos Llc Carboxylic acid derivatives comprising four cycles acting as GLP-1 receptor modulators for therapy of diseases such as diabetes
KR102271179B1 (en) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 Novel glp-1 receptor modulators
MX2017000972A (en) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Novel glp-1 receptor modulators.
WO2016094729A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
US10308677B2 (en) * 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
US9969769B2 (en) 2014-12-19 2018-05-15 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
JP7189369B2 (en) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド Compounds for inhibition of alpha4beta7 integrin
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
JP7189368B2 (en) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド Compounds for inhibition of alpha4beta7 integrin
JP7214882B2 (en) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
JPH04154732A (en) * 1990-10-18 1992-05-27 Nippon Kayaku Co Ltd Optical resolution method
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
US5648368A (en) * 1992-12-01 1997-07-15 Merck & Co., Inc. Fibrinogen receptor antagonists
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH0873422A (en) * 1994-09-07 1996-03-19 Kdk Corp New amino acid ester and method for detecting leukocyte, esterase or protease
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
IL133637A0 (en) 2001-04-30
KR20010022405A (en) 2001-03-15
PL338457A1 (en) 2000-11-06
HUP0003921A2 (en) 2001-02-28
EP0994896A1 (en) 2000-04-26
WO1999006437A1 (en) 1999-02-11
CA2290748A1 (en) 1999-02-11
JP2001512139A (en) 2001-08-21
NO20000452D0 (en) 2000-01-28
AU8823498A (en) 1999-02-22
NO20000452L (en) 2000-03-27
CN1265672A (en) 2000-09-06
HUP0003921A3 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
BR9811594A (en) Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion
BR9811598A (en) &#34;carbamyloxy compounds that inhibit vla-4-mediated leukocyte adhesion&#34;.
BR9811569A (en) Compounds that inhibit vla-4-mediated leukocyte adhesion
BR9812114A (en) Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811573A (en) Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812111A (en) Dipeptide and related compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811599A (en) Dipetid compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812118A (en) 4-Amino-phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR0007663A (en) Acyl derivatives for use in the treatment of diseases related to vla-4
BRPI0513143A (en) multivalent vla-4 antagonists comprising polymeric moieties
HK1072608A1 (en) Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
AR029611A1 (en) COMPOUNDS THAT INHIBIT THE ADHESION OF LEUCOCITS INTERMEDIATE BY VLA-4
AR026105A1 (en) HETEROARILO, HETEROCICLICO AND ILO COMPUTERS THAT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.